Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZD4R6
|
|||
| Drug Name |
RO7443904
|
|||
| Synonyms |
RG6333
Click to Show/Hide
|
|||
| Drug Type |
Bispecific antibody
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C82-C85; ICD-9: 200, 202] | Phase 1 | [1] | |
| Company |
Roche/Genentech
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05219513) An Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Genentch | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.